- Dr Reddy’s Laboratories Ltd. and RDIF announced that they had begun adaptive phase 2/3 clinical tests for Sputnik V vaccine.
- Twenty-two thousand patients were vaccinated with the first dose of the vaccine.
- Nineteen thousand patients were vaccinated with both the first and second doses of the vaccine.
THDNewsDesk: On Tuesday, Dr Reddy’s Laboratories Ltd. and Russian Direct Investment Fund (RDIF) announced that they had begun adaptive phase 2/3 clinical tests for Sputnik V vaccine in India after obtaining the required permission from the Central Drugs Laboratory, Kasauli, India. This will be a multicentre and randomised controlled research, that will cover safety and immunogenicity research. JSS Medical Research is carrying clinical tests as a clinical examination partner.
Additionally, Dr Reddy’s has allianced with the Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology for consulting and to utilise BIRAC’s clinical test centres for the vaccine. Lately, RDIF declared the second interim review of clinical test data, which noted 91.4 per cent efficiency for the vaccine on day 28 after the first dose; vaccine efficiency over 95 per cent 42 days after the first dose. Recently, 40,000 patients are taking part in Phase III of Sputnik V clinical tests, out of which over 22,000 were vaccinated, with the first dose of the vaccine. Over 19,000 patients were vaccinated, with both the first and second doses of the vaccine.
G V Prasad, Co-Chairman and Managing Director, Dr Reddy’s Laboratories, said, “This is another significant step as we continue to collaborate with multiple entities along with the government bodies to fast-track the process for launching the vaccine in India. We are working towards making the vaccine available with a combination of import and indigenous production model.”